Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
Lung cancer causes significant morbidity and mortality in China and worldwide. In China, lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer (NSCLC) is the predominant type of lung cancer, accounting for approximately 80%–85% of all lung cancer cases. Immunoth...
में बचाया:
| मुख्य लेखकों: | , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Frontiers Media S.A.
2021-11-01
|
| श्रृंखला: | Frontiers in Oncology |
| विषय: | |
| ऑनलाइन पहुंच: | https://www.frontiersin.org/articles/10.3389/fonc.2021.757993/full |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|